Galderma priced its initial IPO on SIX Swiss Exchange at CHF 53 per share and closed at CHF 64 per share at the end of the first trading day, implying a market capitalisation of CHF 15 billion (USD 17 billion).

Our team advised EQT on the Luxembourg corporate and financial aspects.

After being acquired by EQT Private Equity and a consortium of co-investors, Galderma has evolved from being a non-core subsidiary of Nestlé to becoming a prominent leader in the dermatology sector, focusing solely on this category.

Galderma has leading positions across three of the most attractive market segments – Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology – and a presence in more than 90 countries with one of the broadest portfolios of clinically proven flagship brands in dermatology.

EQT is a purpose-driven global investment organisation focused on active ownership strategies.